Asuragen Launches miRNA Rx Spinout | GenomeWeb
NEW YORK (GenomeWeb News) – Asuragen today announced that it has spun out its microRNA-based therapeutics intellectual property into a new company called Mirna Therapeutics.
Specific details about the structure and focus of Mirna were not disclosed.
“The discovery of miRNAs represents a paradigm-changing event in biology and medicine of a magnitude that only occurs once every decade or two," Asuragen CEO and CSO Matt Winkler said in a statement. “They likely will become a major new class of drugs.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.